Amyloid-Fibrinogen Aggregates (“Microclots”) Predict Risks of Disseminated Intravascular Coagulation and Mortality.

Publication date: Mar 20, 2024

Microclots have been associated with various conditions, including post-acute sequelae of SARS-CoV-2 infection. They have been postulated to be amyloid-fibrin(ogen) aggregates, but their role as a prognostic biomarker remains unclear. To examine for their possible clinical utility, blood samples were collected for the first 96 hours from critically ill patients (n=104) admitted to the intensive care unit (ICU). Detection was by staining platelet-poor plasma samples with Thioflavin T and visualized by fluorescent microscopy. Image J software was trained to identify and quantify microclots, which were detected in 44 [42. 3%] patients on ICU admission but not in the remaining 60 [57. 7%] or in 20 healthy controls [0. 0%]. Microclots on admission to ICU were associated with a primary diagnosis of sepsis (microclots present in sepsis=23/44 [52. 3%] vs microclots absent in sepsis=19/60 [31. 7%], P=0. 044). Multicolour immunofluorescence demonstrated that microclots consisted of amyloid-fibrinogen aggregates, which was supported by proteomic analysis. Patients with either a high number or larger-sized microclots had a higher likelihood of developing disseminated intravascular coagulation (DIC) (OR=51. 4 [95% CI=6. 3-6721. 1], P

Concepts Keywords
Amyloid Admission
Blood Aggregates
Hours Amyloid
Immunofluorescence Blood
Poor Coagulation
Conditions
Disseminated
Fibrinogen
Icu
Including
Intravascular
Microclots
Mortality
Predict
Risks

Semantics

Type Source Name
drug DRUGBANK Fibrinogen Human
disease MESH Disseminated Intravascular Coagulation
disease MESH post-acute sequelae of SARS-CoV-2 infection
drug DRUGBANK Estrone sulfate
disease IDO blood
disease MESH critically ill
disease MESH sepsis
drug DRUGBANK Dacarbazine

Original Article

(Visited 1 times, 1 visits today)